Nautilus Biotechnology signs TD Cowen for up to USD 125 million ATM equity offering

Nautilus Biotechnology entered an at-the-market equity distribution agreement with TD Securities (USA) to sell up to USD 125 million of common stock.

TD Securities will act as sales agent. Fees are set at up to 3% of gross proceeds on shares sold.

The program replaces a prior TD Cowen ATM agreement dated Feb. 28, 2024, which was mutually terminated. No shares were sold under it.

Sales can begin once the company’s Form S-3 shelf registration statement is declared effective by the SEC.